NOV 14, 2018 06:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar

Improving Empiric Therapy and Sepsis Management with Same-Day Results from the Lab

C.E. CREDITS: P.A.C.E. CE
Speakers
  • President and CEO, T2 Biosystems
    Biography
      At the helm of T2 Biosystems, Mr. McDonough and his team took a new technology concept from MIT and MGH and grew it into a publicly-traded company that has the first and only FDA-cleared diagnostic products to directly detect sepsis-causing pathogens in blood. T2Direct Diagnostics™ are improving patient care in over 160 hospitals worldwide - helping patients with potentially life-threatening illness receive targeted treatment as much as eight times faster.

    Abstract:

    Sepsis is the Achilles’ heel of health care. Despite being relatively unknown to the public, it is a top killer in hospitals and the cost burden is crushing to our healthcare system. More and more, sepsis is keeping hospital CFO’s up at night and is the focus of widespread hospital initiatives. 

    Hospitals’ top defense against sepsis today is empiric therapy, a probability based approach with broad-spectrum antibiotic care in the absence of species-specific information about the cause of a patient’s infection (if they have an infection at all). Despite the successes of empiric therapy, it is still severely limited by lack of actionable diagnostic information, with studies demonstrating that up to 40% of bloodstream infections receive incorrect treatment.

    In this talk, entrepreneur and CEO John McDonough will share how rapid diagnostics can significantly improve empiric therapy and potentially save lives. New tests allow for more targeted empiric therapy, improving patient outcomes and driving down hospital costs. Mr. McDonough will present on the breakthrough T2Bacteria and T2Candida Panel, the first FDA-cleared tests to directly provide species-specific results for sepsis-causing pathogens in 3 to 5 hours, without the wait for blood culture. 

    Learning Objectives: 

    1. Review the efficacy of empiric therapy for patients at risk of sepsis and blood stream infections
    2. Describe the limitations of current sepsis management
    3. Review T2MR technology for rapid identification of bacterial pathogens
    4. Describe ability for breakthrough diagnostic technology to improve empiric therapy and provide faster, targeted therapy 


    Show Resources
    You May Also Like
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    JUN 26, 2018 06:00 AM PDT
    C.E. CREDITS
    JUN 26, 2018 06:00 AM PDT
    Date: June 26, 2018Time: 6:00 a.m. PDT, 9:00 a.m. EDT, 1500 CEST Today’s hematology analyzers employ various methods for enumerating platelets. These methods include: e...
    JUN 20, 2018 10:00 AM EDT
    C.E. CREDITS
    JUN 20, 2018 10:00 AM EDT
    DATE: June 20, 2018TIME: 07:00AM PDT, 10:00AM EDTIntroducing GE’s New Lyo-StableTM service. Sepsis is one of the top challenges facing hospitals in terms of clinical outcomes...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    SEP 12, 2017 08:00 AM PDT
    SEP 12, 2017 08:00 AM PDT
    DATE: September 12, 2017TIME: 8:00am PT, 11:00am ETEvery year, millions of dollars are wasted on poorly characterized and performing antibodies.  Key researchers in the antibody co...
    Loading Comments...